Bristol-Myers Squibb Company

NYSE: BMY
$56.38
+$0.43 (+0.8%)
Real Time Data Delayed 15 Min.

BMY Articles

Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
A report that activist investor firm Starboard Value had taken a stake in CVS momentarily lifted the drugstore and health insurer's share price.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Many mergers have been announced or have closed, but just seven recent and pending deals have transformed how analysts and investors alike are having to view corporate America.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Both Amgen and Celgene shares made a handy gain on Monday after it was announced that the companies had made an agreement in relation to Celgene’s merger with Bristol-Myers Squibb.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.